CSI Market
Sign In | Register

Eagle Pharmaceuticals inc (EGRX) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access EGRX Annual Cash Flow →
Cash flow patterns shown here provide context for understanding Eagle Pharmaceuticals inc's ability to sustain operations and capital deployment.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2023)
6 Months 		(Mar 31 2023) (Dec 31 2022) (Sep 30 2022) (Jun 30 2022)
Operating Activities
Income10.91
Depreciation & amortization0.22
Amortization of Other Assets11.15
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories4.58
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation8.83
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Adjustments Noncash Itemsto Reconcile Net Income Lossto Cash Providedby Usedin Operating Activities Noncash Interest Expense-
Operating Lease Right Of Use Asset Amortization Expense0.65
Debt Securities Held To Maturity Credit Loss Expense Reversal-
Derivative Gain Loss On Derivative Net-0.08
Amortization Of Inventory Step Up0.74
Increase Decreasein Prepaid Expense and Other Current Assets Total-1.07
Income taxes-3.97
Unrealized Gain (Loss) on Investments0.19
Increase (Decrease) in Accounts Receivable-42.70
Increase (Decrease) in Accounts Payable-3.15
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-19.18
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital-0.76
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-33.64
Investing Activities
Capital Expenditures-0.06
Sale of Capital Items0.00
Proceeds from Sale, Maturity and Collection of Short-term Investments0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payments To Acquire Equity Securities Fv Ni-12.50
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Payments to Acquire Notes Receivable0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-12.56
Financing Activities
Short-term debt Net10.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-2.50
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-56.59
Proceeds from Issuance of Convertible Notes and Warrants-
Deferred Financingcosts-
Deferred I P O Costs-
Income Taxes Paid Franchise Taxes Paid-
Accrued Stock Issuance Costs-
Debt Conversion Converted Instrument Amount-
Conversion Of Stock Amount Converted-
Payments for Contingent Consideration-
Payments For Employee Options Exercised-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents55.32
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities6.24
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-33.70
Total Cash Flow-39.97
4 historic quarters locked

Sign in to unlock the full Eagle Pharmaceuticals inc cash flow history.

Sign In Create Free Account

About Eagle Pharmaceuticals Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000827871-23-000024

Figures are derived from filed reports and may be restated. Historical data is subject to revision.